14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.91 $2.61 Friday, 3rd May 2024 CHRS stock ended at $2.27. This is 4.61% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 6.02% from a day low at $2.19 to a day high of $2.32.
90 days $1.91 $2.87
52 weeks $1.44 $8.22

Historical Coherus BioSciences prices

Date Open High Low Close Volume
Mar 30, 2023 $6.50 $6.56 $6.36 $6.43 1 156 272
Mar 29, 2023 $6.49 $6.54 $6.31 $6.48 918 872
Mar 28, 2023 $6.34 $6.55 $6.28 $6.42 1 265 051
Mar 27, 2023 $6.05 $6.18 $5.97 $6.00 757 658
Mar 24, 2023 $5.89 $6.08 $5.81 $6.00 704 562
Mar 23, 2023 $6.00 $6.10 $5.81 $5.90 1 117 951
Mar 22, 2023 $6.11 $6.17 $5.87 $5.89 1 147 149
Mar 21, 2023 $6.31 $6.36 $6.05 $6.10 907 148
Mar 20, 2023 $6.03 $6.34 $5.99 $6.26 937 922
Mar 17, 2023 $6.35 $6.44 $6.05 $6.08 2 111 078
Mar 16, 2023 $6.31 $6.49 $6.06 $6.37 827 074
Mar 15, 2023 $6.34 $6.49 $6.04 $6.39 2 123 061
Mar 14, 2023 $6.68 $6.75 $6.25 $6.35 1 262 197
Mar 13, 2023 $6.20 $6.53 $6.01 $6.37 1 120 407
Mar 10, 2023 $6.37 $6.37 $5.71 $6.07 1 575 468
Mar 09, 2023 $6.86 $6.94 $6.24 $6.24 1 668 106
Mar 08, 2023 $7.25 $7.39 $6.73 $6.90 1 550 719
Mar 07, 2023 $6.53 $7.34 $6.36 $7.30 1 973 506
Mar 06, 2023 $7.24 $7.28 $6.72 $6.77 1 487 512
Mar 03, 2023 $6.86 $7.07 $6.66 $7.06 861 895
Mar 02, 2023 $6.82 $6.85 $6.54 $6.80 1 921 500
Mar 01, 2023 $6.75 $6.88 $6.62 $6.74 737 797
Feb 28, 2023 $6.92 $7.02 $6.74 $6.77 982 409
Feb 27, 2023 $7.04 $7.22 $6.96 $6.99 991 637
Feb 24, 2023 $7.10 $7.21 $6.91 $6.94 740 256
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT